Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 8/2008

01.08.2008 | Review Article

Bipolar Disorder and the Metabolic Syndrome

Causal Factors, Psychiatric Outcomes and Economic Burden

verfasst von: Dr Andrea Fagiolini, K. N. Roy Chengappa, Isabella Soreca, Jane Chang

Erschienen in: CNS Drugs | Ausgabe 8/2008

Einloggen, um Zugang zu erhalten

Abstract

Overweight and obesity are highly prevalent in patients with bipolar disorder, and metabolic disorders also affect a significant portion of this population. Obesity and metabolic disorders cause significant economic burden and impair quality of life in both the general population and patients with bipolar disorder. This review examines the relationship between bipolar disorder and the metabolic syndrome, and the associated economic impact.
The metabolic syndrome and bipolar disorder appear to share common risk factors, including endocrine disturbances, dysregulation of the sympathetic nervous system, and behaviour patterns, such as physical inactivity and overeating. In addition, many of the commonly used pharmacological treatments for bipolar disorder may intensify the medical burden in bipolar patients by causing weight gain and metabolic disturbances, including alterations in lipid and glucose metabolism, which can result in an increased risk for diabetes mellitus, hypertension, dyslipidaemia, cardiovascular disease and the metabolic syndrome. These medical co-morbidities and obesity have been associated with a worse disease course and likely contribute to the premature mortality observed in bipolar patients. Weight gain is also a major cause of treatment noncompliance, increased use of outpatient and inpatient services and, consequently, higher healthcare costs. Prevention of weight gain and metabolic disturbances or early intervention when these are present in bipolar disorder could result in significant health and economic benefits.
Literatur
1.
Haslam DW, James WP. Obesity. Lancet 2005; 366(9492): 1197–209PubMed
2.
Behn A, Ur E. The obesity epidemic and its cardiovascular consequences. Curr Opin Cardiol 2006; 21(4): 353–60PubMed
3.
4.
Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360(9343): 1347–60PubMed
5.
James PT, Rigby N, Leach R. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil 2004; 11(1): 3–8PubMed
6.
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106 (25): 3143-421
7.
Laaksonen DE, Lakka HM, Niskanen LK, et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002; 156(11): 1070–7PubMed
8.
Saely CH, Aczel S, Marte T, et al. The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab 2005; 90(10): 5698–703PubMed
9.
Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24(4): 683–9PubMed
10.
Hu G, Qiao Q, Tuomilehto J, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164(10): 1066–76PubMed
11.
Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288(21): 2709–16PubMed
12.
Definition, diagnosis and classification of diabetes mellitus and its complications: part 1. Diagnosis and classification of diabetes mellitus. Geneva: World Health Organization, 1999. Report no. 99.2
13.
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific statement. Circulation 2005; 112(17): 2735–52PubMed
14.
Alberti G. Introduction to the metabolic syndrome. Eur Heart J 2005; 7Suppl. D: D3–5
15.
16.
Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004; 27(10): 2444–9PubMed
17.
Thompson D, Edelsberg J, Colditz GA, et al. Lifetime health and economic consequences of obesity. Arch Intern Med 1999; 159(18): 2177–83PubMed
18.
Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world: a growing challenge. N Engl J Med 2007; 356(3): 213–5PubMed
19.
Jia H, Lubetkin EI. The impact of obesity on health-related quality-of-life in the general adult US population. J Public Health (Oxf) 2005; 27(2): 156–64
20.
Sach TH, Barton GR, Doherty M, et al. The relationship between body mass index and health-related quality of life: comparing the EQ-5D, EuroQol VAS and SF-6D. Int J Obes (Lond) 2007; 31(1): 189–96
21.
Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiatry 2003; 64(12): 1426–35PubMed
22.
Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002; 288(14): 1723–7PubMed
23.
McElroy SL, Frye MA, Suppes T, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002; 63(3): 207–13PubMed
24.
Fagiolini A, Kupfer DJ, Houck PR, et al. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry 2003; 160(1): 112–7PubMed
25.
Fagiolini A, Frank E, Scott JA, et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005; 7(5): 424–30PubMed
26.
Basu R, Brar JS, Chengappa KN, et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder: bipolar subtype. Bipolar Disord 2004; 6(4): 314–8PubMed
27.
Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999; 156(9): 1417–20PubMed
28.
Johannessen L, Strudsholm U, Foldager L, et al. Increased risk of hypertension in patients with bipolar disorder and patients with anxiety compared to background population and patients with schizophrenia. J Affect Disord 2006; 95(1–3): 13–7PubMed
29.
Kilbourne AM. The burden of general medical conditions in patients with bipolar disorder. Curr Psychiatry Rep 2005; 7(6): 471–7PubMed
30.
Elmslie JL, Silverstone JT, Mann JI, et al. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry 2000; 61(3): 179–84PubMed
31.
Malhotra S, McElroy SL. Associations between metabolic syndrome and psychiatric disorder. Prim Psychiatry 2003; 10(11): 37–44
32.
Taylor V, Macqueen G. Associations between bipolar disorder and metabolic syndrome: a review. J Clin Psychiatry 2006; 67(7): 1034–41PubMed
33.
Newcomer JW, Craft S, Fucetola R, et al. Glucose-induced increase in memory performance in patients with schizophrenia. Schizophr Bull 1999; 25(2): 321–35PubMed
34.
Regenold WT, Thapar RK, Marano C, et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002; 70(1): 19–26PubMed
35.
Ruzickova M, Slaney C, Garnham J, et al. Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can J Psychiatry 2003; 48(7): 458–61PubMed
36.
Daban C, Vieta E, Mackin P, et al. Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr Clin North Am 2005; 28(2): 469–80PubMed
37.
Watson S, Gallagher P, Ritchie JC, et al. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry 2004; 184: 496–502PubMed
38.
Brindley DN, Rolland Y. Possible connections between stress, diabetes, obesity, hypertension and altered lipoprotein metabolism that may result in atherosclerosis. Clin Sci (Lond) 1989; 77(5): 453–61
39.
Rosmond R, Bjorntorp P. The interactions between hypothalamic-pituitary-adrenal axis activity, testosterone, insulin-like growth factor I and abdominal obesity with metabolism and blood pressure in men. Int J Obes Relat Metab Disord 1998; 22(12): 1184–96PubMed
40.
Goodwin FK, Jamison KR. Manic-depressive illness: bipolar disorders and recurrent depression. 2nd ed. New York: Oxford University Press, 2007
41.
Roos A, Bakker SJ, Links TP, et al. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab 2007; 92(2): 491–6PubMed
42.
Kleiner J, Altshuler L, Hendrick V, et al. Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment. J Clin Psychiatry 1999; 60(4): 249–55PubMed
43.
Walsh JP, Bremner AP, Bulsara MK, et al. Thyroid dysfunction and serum lipids: a community-based study. Clin Endocrinol (Oxf) 2005; 63(6): 670–5
44.
Monzani F, Dardano A, Caraccio N. Does treating subclinical hypothyroidism improve markers of cardiovascular risk? Treat Endocrinol 2006; 5(2): 65–81PubMed
45.
Fagiolini A, Kupfer DJ, Scott J, et al. Hypothyroidism in patients with bipolar I disorder treated primarily with lithium. Epidemiol Psichiatr Soc 2006; 15(2): 123–7PubMed
46.
Hendrick V, Altshuler L, Whybrow P. Psychoneuroendocrinology of mood disorders: the hypothalamic-pituitary-thyroid axis. Psychiatr Clin North Am 1998; 21(2): 277–92PubMed
47.
Vincent A, Baruch P, Vincent P. Early onset of lithium-associated hypothyroidism. J Psychiatry Neurosci 1993; 18(2): 74–7PubMed
48.
Klumpers UM, Boom K, Janssen FM, et al. Cardiovascular risk factors in outpatients with bipolar disorder. Pharmacopsychiatry 2004; 37(5): 211–6PubMed
49.
Angst F, Stassen HH, Clayton PJ, et al. Mortality of patients with mood disorders: follow-up over 34–38 years. J Affect Disord 2002; 68(2–3): 167–81PubMed
50.
Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 58(9): 844–50PubMed
51.
Zahn TP, Nurnberger Jr JI, Berrettini WH. Electrodermal activity in young adults at genetic risk for affective disorder. Arch Gen Psychiatry 1989; 46(12): 1120–4PubMed
52.
Lake CR, Pickar D, Ziegler MG, et al. High plasma norepinephrine levels in patients with major affective disorder. Am J Psychiatry 1982; 139(10): 1315–8PubMed
53.
Landsberg L. Role of the sympathetic adrenal system in the pathogenesis of the insulin resistance syndrome. Ann N Y Acad Sci 1999; 892: 84–90PubMed
54.
Rosmond R, Bjorntorp P. Blood pressure in relation to obesity, insulin and the hypothalamic-pituitary-adrenal axis in Swedish men. J Hypertens 1998; 16 (12 Pt 1): 1721–6PubMed
55.
Attvall S, Fowelin J, Lager I, et al. Smoking induces insulin resistance: a potential link with the insulin resistance syndrome. J Intern Med 1993; 233(4): 327–32PubMed
56.
Grant BF, Hasin DS, Chou SP, et al. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2004; 61(11): 1107–15PubMed
57.
Vornik LA, Brown ES. Management of comorbid bipolar disorder and substance abuse. J Clin Psychiatry 2006; 67Suppl. 7: 24–30PubMed
58.
Virmani A, Binienda Z, Ali S, et al. Links between nutrition, drug abuse, and the metabolic syndrome. Ann N Y Acad Sci 2006; 1074(1): 303–14PubMed
59.
McIntyre RS, Konarski JZ, Misener VL, et al. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 2005; 17(2): 83–93PubMed
60.
Grant BF, Stinson FS, Dawson DA, et al. Prevalence and cooccurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004; 61(8): 807–16PubMed
61.
Wildes JE, Marcus MD, Fagiolini A. Obesity in patients with bipolar disorder: a biopsychosocial-behavioral model. J Clin Psychiatry 2006; 67(6): 904–15PubMed
62.
Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286(10): 1195–200PubMed
63.
Elmslie JL, Mann JI, Silverstone JT, et al. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 2001; 62(6): 486–91PubMed
64.
Soreca I, Mauri M, Castrogiovanni S, et al. Measured and expected resting energy expenditure in patients with bipolar disorder on maintenance treatment. Bipolar Disord 2007; 9(7): 784–8PubMed
65.
Balleine BW. Neural bases of food-seeking: affect, arousal and reward in corticostriatolimbic circuits. Physiol Behav 2005; 86(5): 717–30PubMed
66.
Cannon CM, Palmiter RD. Reward without dopamine. J Neurosci 2003; 23(34): 10827–31PubMed
67.
Blum K, Sheridan PJ, Wood RC, et al. The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med 1996; 89(7): 396–400PubMed
68.
Levitan RD, Masellis M, Lam RW, et al. Childhood inattention and dysphoria and adult obesity associated with the dopamine D4 receptor gene in overeating women with seasonal affective disorder. Neuropsychopharmacology 2004; 29(1): 179–86PubMed
69.
Comings DE, Blum K. Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog Brain Res 2000; 126: 325–41PubMed
70.
Levitan RD, Masellis M, Basile VS, et al. The dopamine-4 receptor gene associated with binge eating and weight gain in women with seasonal affective disorder: an evolutionary perspective. Biol Psychiatry 2004; 56(9): 665–9PubMed
71.
Ramacciotti CE, Paoli RA, Marcacci G, et al. Relationship between bipolar illness and binge-eating disorders. Psychiatry Res 2005; 135(2): 165–70PubMed
72.
Kruger S, Shugar G, Cooke RG. Comorbidity of binge eating disorder and the partial binge eating syndrome with bipolar disorder. Int J Eat Disord 1996; 19(1): 45–52PubMed
73.
McLaren KD, Marangell LB. Special considerations in the treatment of patients with bipolar disorder and medical comorbidities. Ann Gen Hosp Psychiatry 2004; 3(1): 7PubMed
74.
Cradock-O’Leary J, Young AS, Yano EM, et al. Use of general medical services by VA patients with psychiatric disorders. Psychiatr Serv 2002; 53(7): 874–8PubMed
75.
McIntyre RS, Soczynska JK, Konarski JZ, et al. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 2006; 5(1): 157–68PubMed
76.
Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61Suppl. 11: 37–41PubMed
77.
Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57(5): 481–9
78.
Vendsborg PB, Bech P, Rafaelsen OJ. Lithium treatment and weight gain. Acta Psychiatr Scand 1976; 53(2): 139–47PubMed
79.
Bosch F, Rodriguez-Gil JE, Hatzoglou M, et al. Lithium inhibits hepatic gluconeogenesis and phosphoenolpyruvate carboxykinase gene expression. J Biol Chem 1992; 267(5): 2888–93PubMed
80.
Chen X, McMahon EG, Gulve EA. Stimulatory effect of lithium on glucose transport in rat adipocytes is not mediated by elevation of IP 1. Am J Physiol 1998; 275 (2 Pt 1): E272–7PubMed
81.
Breum L, Astrup A, Gram L, et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992; 41(6): 666–70PubMed
82.
Sachs G, Bowden C, Calabrese JR, et al. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disord 2006; 8(2): 175–81PubMed
83.
Ketter TA, Kalali AH, Weisler RH. A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004; 65(5): 668–73PubMed
84.
Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27 (2): 596-601
85.
Marken PA, Pies RW. Emerging treatments for bipolar disorder: safety and adverse effect profiles (CE). Ann Pharmacother 2006 Feb; 40(2): 276–85PubMed
86.
Kim SF, Huang AS, Snowman AM, et al. Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. PNAS 2007; 104(9): 3456–9PubMed
87.
Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 2005; 66(4): 504–14PubMed
88.
Ader M, Kim SP, Catalano KJ, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005; 54(3): 862–71PubMed
89.
Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003; 160(7): 1263–71PubMed
90.
Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162(7): 1281–90PubMed
91.
Fagiolini A. Battling bipolar disorder: therapeutic approaches. Clin Advis 2005 Mar; Suppl.: 11-20
92.
Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA 2005; 293(20): 2528–30PubMed
93.
94.
Black DW, Winokur G, Hulbert J, et al. Predictors of immediate response in the treatment of mania: the importance of comorbidity. Biol Psychiatry 1988; 24(2): 191–8PubMed
95.
Black DW, Winokur G, Bell S, et al. Complicated mania: comorbidity and immediate outcome in the treatment of mania. Arch Gen Psychiatry 1988; 45(3): 232–6PubMed
96.
Black DW, Hulbert J, Nasrallah A. The effect of somatic treatment and comorbidity on immediate outcome in manic patients. Compr Psychiatry 1989; 30(1): 74–9PubMed
97.
Hajek T, Slaney C, Garnham J, et al. Clinical correlates of current level of functioning in primary care-treated bipolar patients. Bipolar Disord 2005; 7(3): 286–91PubMed
98.
Bhargava A. A longitudinal analysis of the risk factors for diabetes and coronary heart disease in the Framingham Offspring Study. Popul Health Metr 2003; 1(1): 3PubMed
99.
Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004; 89(6): 2595–600PubMed
100.
Hanley AJ, Williams K, Festa A, et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2004; 53(10): 2623–32PubMed
101.
Hanson RL, Imperatore G, Bennett PH, et al. Components of the “metabolic syndrome” and incidence of type 2 diabetes. Diabetes 2002; 51(10): 3120–7PubMed
102.
Stern MP, Williams K, Gonzalez-Villalpando C, et al. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004; 27(11): 2676–81PubMed
103.
Alexander CM, Landsman PB, Teutsch SM, et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52(5): 1210–4PubMed
104.
Bonora E, Targher G, Formentini G, et al. The Metabolic Syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabet Med 2004; 21(1): 52–8PubMed
105.
Krishnan KR. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med 2005; 67(1): 1–8PubMed
106.
Kilbourne AM, Cornelius JR, Han X, et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord 2004; 6(5): 368–73PubMed
107.
Kolotkin RL, Crosby RD, Corey-Lisle PK, et al. Performance of a weight-related measure of quality of life in a psychiatric sample. Qual Life Res 2006; 15(4): 587–96PubMed
108.
Fagiolini A, Frank E, Houck PR, et al. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry 2002; 63(6): 528–33PubMed
109.
Hamilton M. A rating sale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62PubMed
110.
Thase ME, Carpenter L, Kupfer DJ, et al. Clinical significance of reversed vegetative subtypes of recurrent major depression. Psychopharmacol Bull 1991; 27: 17–22PubMed
111.
Thompson WK, Kupfer DJ, Fagiolini A, et al. Prevalence and clinical correlates of medical comorbidities in patients with bipolar I disorder: analysis of acute-phase data from a randomized controlled trial. J Clin Psychiatry 2006; 67(5): 783–8PubMed
112.
Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness: 1991. Soc Psychiatry Psychiatr Epidemiol 1995; 30(5): 213–9PubMed
113.
Bryant-Comstock L, Stender M, Devercelli G. Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disord 2002; 4(6): 398–405PubMed
114.
Gardner HH, Kleinman NL, Brook RA, et al. The economic impact of bipolar disorder in an employed population from an employer perspective. J Clin Psychiatry 2006; 67(8): 1209–18PubMed
115.
Brook RA, Rajagopalan K, Kleinman NL, et al. Incurring greater health care costs: risk stratification of employees with bipolar disorder. Prim Care Companion J Clin Psychiatry 2006; 8(1): 17–24PubMed
116.
Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 2005; 118Suppl. 2: 15–22S
117.
Aronne LJ, Segal KR. Weight gain in the treatment of mood disorders. J Clin Psychiatry 2003; 64Suppl. 8: 22–9PubMed
118.
Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62Suppl. 7: 22–31PubMed
119.
Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001; 52(6): 805–11PubMed
120.
Li J, McCombs JS, Stimmel GL. Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program. J Affect Disord 2002; 71(1–3): 131–9PubMed
121.
Fleming T, editor. Red book: pharmacy’s fundamental reference. Montvale (NJ): Thomson Healthcare, 2007
122.
Shah A, Shen N, El Mallakh RS. Weight gain occurs after onset of bipolar illness in overweight bipolar patients. Ann Clin Psychiatry 2006; 18(4): 239–41PubMed
Metadaten
Titel
Bipolar Disorder and the Metabolic Syndrome
Causal Factors, Psychiatric Outcomes and Economic Burden
verfasst von
Dr Andrea Fagiolini
K. N. Roy Chengappa
Isabella Soreca
Jane Chang
Publikationsdatum
01.08.2008
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 8/2008
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200822080-00004

Weitere Artikel der Ausgabe 8/2008

CNS Drugs 8/2008 Zur Ausgabe

Original Research Article

A Randomized, Double-Blind, Crossover Study of Once-Daily Dexmethylphenidate in Children with Attention-Deficit Hyperactivity Disorder

Review Article

Delirium and its Treatment

Leading Article

Novel Thrombolytic Drugs

Review Article

Efficacy and Tolerability of Pharmacotherapies for Borderline Personality Disorder

Review Article

Role of Cannabinoids in the Management of Neuropathic Pain

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

22.04.2024 | DGIM 2024 | Nachrichten

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

18.04.2024 | Arterielle Hypertonie | Nachrichten

Antihypertensiva schützen auch alte Menschen noch vor Demenz

18.04.2024 | Spinale Muskelatrophien | Nachrichten

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Manche Gestagene können das Risiko für Meningeome erhöhen
weitere anzeigen

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise